SCHEMBL971599

SCHEMBL971599

CCCCCCCC(=O)CCc1ccc(O)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
CYP2C8 P10632 5/20 1.00
CYP2C9 P11712 5/20 1.00
CYP2B6 P20813 5/20 1.00
CYP2C19 P33261 5/20 1.00
CYP1A2 P05177 4/20 1.00
ALOX5 P09917 3/20 0.73
HTR1A P08908 5/20 0.72
CYP2D6 P10635 3/20 0.72
CYP2A6 P11509 3/20 0.72
LTA4H P09960 3/20 0.72
CYP2E1 P05181 2/20 0.72
TRPV1 Q8NER1 3/20 0.72
OR51E2 Q9H255 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877010 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL29711594 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL30417499 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL4881362 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL29371372 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL29801887 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL29805047 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL4883880 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL4885822 1.00 CYP3A4 (1.00) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19
SCHEMBL17546694 0.99 CYP3A4 (0.97) CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683527-A1 VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2026-01-28 EP claimed
US-12497381-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-12-16 US claimed
US-12478091-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-11-25 US claimed
WO-2025202300-A1 COMPLEX COACERVATES FOR NUTRACEUTICALS NEKTIUM PHARMA S.L. (ES) 2025-10-02 WO claimed
EP-4623703-A1 COMPLEX COACERVATES FOR NUTRACEUTICALS Nektium Pharma S.L. (ES) 2025-10-01 EP claimed
US-20250289796-A1 COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2025-09-18 US claimed
EP-4599698-A1 PRODUCTS COMPRISING SENSORY AGENTS Nicoventures Trading Limited (GB) 2025-08-13 EP claimed
US-12358888-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-07-15 US claimed
US-12358889-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-07-15 US claimed
EP-3515215-B1 AGENTS FOR MODULATING THE SENSORY IMPACT OF TOBACCO OR HERBAL SMOKE SENTIENS LLC (US) 2025-06-11 EP claimed
WO-2013185843-A1 COSMETIC COMPOSITIONS COMPRISING HYALURONAN BIOSYNTHESIS PROMOTING AGENTS SYMRISE AG (DE) 2013-12-19 WO claimed
US-8592621-B2 Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease SYMRISE AG (DE) 2013-11-26 US claimed
WO-2013090410-A1 DEVICE AND METHOD FOR SIMULATING CHEMOSENSATION OF SMOKING SENTIENS, LLC (US) 2013-06-20 WO claimed
US-20130152956-A1 DEVICE AND METHOD FOR SIMULATING CHEMOSENSATION OF SMOKING SENTIENS, LLC (US) 2013-06-20 US claimed
US-20110045069-A1 PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE SYMRISE GMBH CO. KG (DE) 2011-02-24 US claimed
WO-2010062581-A2 A BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-06-03 WO claimed
US-20100105644-A1 BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-04-29 US claimed
US-20040156799-A1 Cancer treatment method and compositions REGENTS OF THE UNIVERSITY OF MINNESOTA 2004-08-12 US claimed
EP-1392266-A2 CANCER TREATMENT METHOD AND COMPOSITIONS COMPRISING COMPOUNDS OF THE GINGER FAMILY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2004-03-03 EP claimed
WO-2002098399-A2 CANCER TREATMENT METHOD AND COMPOSITIONS COMPRISING COMPOUNDS OF THE GINGER FAMILY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2002-12-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040156799-A1 Cancer treatment method and compositions H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS, TP53 CYP3A4 2758/4885CYP2C8 3585/4885CYP2C9 3381/4885
US-20100105644-A1 BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF CUTA, COL14A1, BACH1 CYP3A4 2202/4885CYP2C8 958/4885CYP2C9 1615/4885
US-20250289796-A1 COMPOSITIONS AND METHODS OF USE THEREOF OR10J3, TRPA1, TAS2R3 CYP3A4 1035/4885CYP2C8 627/4885CYP2C9 794/4885
US-12358888-B2 Vaporizable alkaloid compositions and methods of use thereof SRM, SCLY, SMOX CYP3A4 823/4885CYP2C8 493/4885CYP2C9 279/4885
US-12358889-B2 Vaporizable alkaloid compositions and methods of use thereof SRM, SCLY, SMOX CYP3A4 823/4885CYP2C8 493/4885CYP2C9 279/4885
US-12497381-B2 Vaporizable alkaloid compositions and methods of use thereof CHRM5, NNMT, CHRM1 CYP3A4 301/4885CYP2C8 583/4885CYP2C9 164/4885
US-20110045069-A1 PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE TAS1R2, TAS2R5, TAS2R1 CYP3A4 4088/4885CYP2C8 4141/4885CYP2C9 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.